

# De Novo Design of Allosteric Control into Rotary Motor V<sub>1</sub>-ATPase by Restoring Lost Function

*Takahiro Kosugi*<sup>1,2,3\*</sup>, *Tatsuya Iida*<sup>4,5</sup>, *Mikio Tanabe*<sup>6</sup>, *Ryota Iino*<sup>4,5</sup>, *Nobuyasu Koga*<sup>1,2,3\*</sup>

<sup>1</sup>Research Center of Integrative Molecular Systems, Institute for Molecular Science (IMS), National Institutes of National Sciences (NINS), Okazaki, Aichi, 444-8585, Japan

<sup>2</sup>Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of National Sciences, Okazaki, Aichi, 444-8585, Japan

<sup>3</sup>Department of Structural Molecular Science, School of Physical Sciences, SOKENDAI (The Graduate University for Advanced Studies), Hayama, Kanagawa, 240-0193, Japan

<sup>4</sup>Department of Life and Coordination-Complex Molecular Science, Institute for Molecular Science (IMS), National Institutes of National Sciences (NINS), Okazaki, Aichi, 444-8585, Japan

<sup>5</sup>Department of Functional Molecular Science, School of Physical Sciences, SOKENDAI (The Graduate University for Advanced Studies), Hayama, Kanagawa, 240-0193, Japan

<sup>6</sup>Structural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, 305-0801, Japan

\* To whom correspondence should be addressed. Tel: 81-564-55-7379. E-mail: [takahirokosugi@ims.ac.jp](mailto:takahirokosugi@ims.ac.jp) or [nkoga@ims.ac.jp](mailto:nkoga@ims.ac.jp)

## 21 **Abstract**

22 Protein complexes exert various functions through allosterically controlled cooperative work. De  
23 novo design of allosteric control into protein complexes provides understanding of their working  
24 principles and potential tools for synthetic biology. Here, we hypothesized that an allosteric control  
25 can be created by restoring lost functions of pseudo-enzymes contained as subunits in protein  
26 complexes. This was demonstrated by computationally de novo designing ATP binding ability of the  
27 pseudo-enzyme subunits in a rotary molecular motor,  $V_1$ -ATPase. Single molecule experiments with  
28 solved crystal structures revealed that the designed  $V_1$  is allosterically accelerated than the wild-type  
29 by the ATP binding to the created allosteric site and the rate is tunable by modulating the binding  
30 affinity. This work opened up an avenue for programming allosteric control into proteins exhibiting  
31 concerted functions.

32 Protein complexes exert their various functions through the cooperative work between their  
33 constituent subunits<sup>1,2</sup>. The orchestration between the subunits is enabled by the allosteric mechanism,  
34 in which a protein function in an active site is controlled by the response to stimuli that occurs at a site  
35 away from the active site<sup>3</sup>. The design of allosteric control into protein complexes to reveal their  
36 working principles and provide novel functionalities has been attempted<sup>4-9</sup>. One of these approaches  
37 is to create fusion proteins between the target protein, whose functions are to be controlled, and a  
38 protein undergoing conformational changes in response to stimuli, such as the binding of an effector  
39 molecule<sup>6,7</sup> or light absorption<sup>8,9</sup>. Nakamura *et al.* created the remotely controlled linear motor protein  
40 with a light-sensitive domain<sup>8</sup>. In this study, we sought an approach to program allosteric control into  
41 protein complexes by creating binding sites for an allosteric effector molecule in the complexes.

42 We focused on pseudo-enzymes, which are homologs of some enzymes but are proven or predicted  
43 to have lost their enzymatic activity<sup>10-12</sup>. The overall structures of pseudo-enzymes are similar to those  
44 of the enzymes, but the conserved amino acids required for their functions are lost from the active  
45 sites; therefore, these sites are called pseudo-active sites. Interestingly, it has been reported that such  
46 pseudo-enzymes exhibit allosteric control when they form complexes<sup>10,11</sup>. For example, a complex-  
47 forming pseudo-kinase—the pseudo-active site can bind ATP but has lost kinase activity—activates  
48 the catalytic function of a complex-forming partner protein, by ATP binding at the pseudo-active

49 site<sup>13,14</sup>. Here, we hypothesized that an allostery can be de novo designed into protein complexes by  
50 restoring the lost function of pseudo-enzymes included in the complexes (Fig. 1a).

51 A pseudo-enzyme is found in a protein complex, the rotary motor V<sub>1</sub>-ATPase (V<sub>1</sub>). V<sub>1</sub> is a part of an  
52 ion pump V-ATPase which transports cations across the membrane by ATP hydrolysis-driven rotation<sup>15</sup>.  
53 The V<sub>1</sub> consists of a rotor composed of the D- and F- subunits and the stator of the hexameric ring  
54 composed of three A-subunits and three B-subunits (Fig. 1b)<sup>16</sup>. The B-subunit is a pseudo-enzyme of  
55 the A-subunit and has homology with the A-subunit (e.g. for *Enterococcus hirae* V<sub>1</sub>-ATPase, the  
56 BLAST E-value between the subunits is  $4 \times 10^{-22}$ ) and the overall subunit structures resemble each  
57 other (Supplementary Fig. 1). However, the details of their sequences and structures are different,  
58 resulting in the two different interfaces between the A- and B- subunits in the A<sub>3</sub>B<sub>3</sub> hexameric ring.  
59 One is the catalytic interface, at which the A-subunit has an ATP hydrolysis catalytic site, and the other  
60 is the non-catalytic interface, at which the B-subunit has a pseudo-active site, which does not hydrolyze  
61 or even bind ATP<sup>16,17</sup>(Supplementary Fig. 2).

62 The relation of the pseudo-active site to the activity at the active site is reported for V<sub>1</sub>, in which the  
63 mutations in the pseudo-active site decrease its activity<sup>18,19</sup>. Furthermore, a study on the rotary motor  
64 F<sub>1</sub>-ATPase from the thermophilic *Bacillus* PS3, which shares a common ancestor with V<sub>1</sub>-ATPase<sup>20</sup>,  
65 reported the relationship between the pseudo-active site and the active site in the rotational

66 mechanism<sup>21</sup>. Similar to  $V_1$ ,  $F_1$  has the stator  $\alpha_3\beta_3$  ring complex, in which the  $\beta$ -subunit has ATP  
67 hydrolase ability, while the  $\alpha$ -subunit, a pseudo-enzyme subunit of the  $\beta$ -subunit, can bind but not  
68 hydrolyze ATP<sup>20,22</sup>. The mutation in the pseudo-active site in the  $\alpha$ -subunit, which significantly  
69 decrease the ATP binding ability, was found to cause  $F_1$  to have long pauses more frequently than the  
70 wild-type. This is likely because of the impeded release of ADP at the active site, indicating that the  
71 pseudo-active site away from the active site allosterically impacts on the active site's function<sup>21</sup>. This  
72 study leads to the hypothesis that the pseudo-active site in the non-catalytic interface of  $V_1$ , which does  
73 not have ATP binding ability<sup>16,17</sup>, can be a target for de novo design of a binding site for an allosteric  
74 effector molecule. We tested this hypothesis by computationally designing an ATP-binding site at the  
75 pseudo-active site in *Enterococcus hirae*  $V_1$ -ATPase.

## 76 **Results**

### 77 **Computational design of an allosteric site in the pseudo-active site**

78 The pseudo-active site in the B-subunit does not have space for nucleotide binding or the well-known  
79 loop motif for phosphate binding, the Walker-A motif (GX<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>GK[T/S])<sup>23,24</sup>, also called a P-loop  
80 (Supplementary Fig. 2). Recently, computational methods for designing small molecule binding  
81 proteins have been developed, using Rosetta design software<sup>25-27</sup>. We attempted to computationally  
82 design an ATP binding site de novo together with a P-loop at the pseudo-active site in the B-subunit  
83 monomer, using Rosetta with a set of features for P-loops obtained from statistical analyses of naturally  
84 occurring proteins (Supplementary Fig. 3).

85 First, the backbone structure of the P-loop was built at the pseudo-active site by using the backbone  
86 of the A-subunit's P-loop, considering the P-loop orientation feature (Supplementary Fig. 3a).  
87 Subsequently, side-chain conformations (amino acid sequences) of the P-loop and the surrounding  
88 residues, which have favorable interactions with ATP, are explored with various ATP conformations,  
89 the feature for native P-loops for the conserved amino acid (Gly) at X<sub>3</sub> (Supplementary Fig. 3c), and  
90 the typical distances between the atoms of the P-loop and the phosphate atoms of ATP (Supplementary  
91 Fig. 3d). The resulting designed structures bound to an ATP were energetically minimized. This  
92 sequence design followed by energy minimization was iterated, and the designs with high ATP binding

93 ability predicted by the Rosetta score were selected; the designs that lost the feature for the conserved  
94 backbone torsion pattern of native P-loops (Supplementary Fig. 3b) during the minimization step were  
95 abandoned. The ATP binding ability of 29 selected designs was further evaluated by short (10 ns)  
96 molecular dynamics simulations for the monomer (Supplementary Fig. 6). Finally, a resulting designed  
97  $V_1$  was experimentally characterized. Details regarding the design procedure is described in Methods  
98 and Supplementary Figs. 4 and 5.

## 99 **Designed B-subunits forms a ring complex with A-subunits**

100 The designed B-subunit (De), expressed with the A-subunit in *E. coli* using the plasmid pTR19-  
101 AB<sup>28</sup> and purified by a Ni<sup>2+</sup>-affinity chromatography followed by size exclusion chromatography,  
102 formed a ring complex with the A-subunit (A<sub>3</sub>(De)<sub>3</sub> ring complex) (Supplementary Fig. 7a).  
103 Subsequently, to evaluate the ATP binding ability of De, we introduced a double mutation in the A-  
104 subunit (K238A and T239A) to significantly impair ATP binding ability<sup>29</sup>. However, De did not form  
105 the A<sub>3</sub>(De)<sub>3</sub> ring complex with the mutant A-subunit (Supplementary Fig. 7b). Therefore, we purified  
106 De as a monomer (Supplementary Fig. 7c) and the nucleotide binding ability was indirectly evaluated  
107 by thermal shift<sup>30</sup> in circular dichroism spectroscopy in the presence or absence of nucleotides  
108 (Supplementary Fig. 8). The De monomer exhibited an increase of its melting temperature upon the  
109 addition of nucleotide, while the melting temperatures for the wild-type B-subunit monomer was  
110 almost the same in the presence and absence of nucleotides, suggesting that De has nucleotide binding  
111 ability. Thus, we attempted to determine the crystal structures of the A<sub>3</sub>(De)<sub>3</sub> complex to prove the  
112 nucleotide-binding ability of De.



## 113 **The designed B-subunit binds to nucleotide**

114 First, the  $A_3(\text{De})_3$  complex was crystallized in the absence of nucleotide and the structure was solved  
115 at 2.77 Å resolution, named  $A_3(\text{De})_3_{\text{empty}}$ . This showed the hexameric ring structure without  
116 nucleotide, which is the same as the wild-type structure (Fig. 2a). The structure of the designed site in  
117 the B-subunit in the crystal structure was almost identical to the computationally designed model  
118 (Supplementary Fig. 9a,b). When we incubated the nucleotide-free crystals with 20 μM AMP-PNP for  
119 5 hours, we found an extra density corresponding to AMP-PNP in a catalytic site. The structure,  
120  $A_3(\text{De})_3_{(\text{ANP})_{1\text{cat}}}$ , was solved at 3.44 Å resolution (Fig. 2b). Next, the nucleotide-free crystals were  
121 incubated for 5 hours with ADP by gradually increasing ADP concentration to 10 mM and the resulting  
122 structure,  $A_3(\text{De})_3_{(\text{ADP}\cdot\text{Pi})_{1\text{cat}}(\text{ADP})_{2\text{cat},2\text{non-cat}}}$ , was solved at 2.90 Å resolution. In  
123  $A_3(\text{De})_3_{(\text{ADP}\cdot\text{Pi})_{1\text{cat}}(\text{ADP})_{2\text{cat},2\text{non-cat}}}$ , each of the three catalytic sites is occupied by ADP (one of the  
124 sites has ADP with a possible Pi) and each of the two sites out of the three design sites is with ADP  
125 (Fig. 2c). This crystal structure proved that the designed site in the non-catalytic interface has the  
126 nucleotide binding ability, although the binding mode was not same as we designed (Supplementary  
127 Fig. 9c,d). Furthermore, the nucleotide-free crystals were incubated overnight by gradually  
128 increasing the ADP concentration to 5 mM and two different structural states in an asymmetric unit  
129 were obtained from one dataset: one is  $A_3(\text{De})_3_{(\text{ADP})_{3\text{cat},1\text{non-cat}}}$ , in which each of the three catalytic

130 sites and one of the designed sites are occupied by ADP (Fig. 2d), and the other is  
131  $A_3(\text{De})_3_{(\text{ADP})_{3\text{cat},2\text{non-cat}}}$ , in which each of the three catalytic sites and each of the two designed sites  
132 are occupied by ADP (Fig. 2e). Although the resolution of these structures is relatively low (3.95 Å),  
133 the densities for the main chain C $\alpha$ -trace and bound ADPs were clearly observed. The nucleotide-  
134 bound state of  $A_3(\text{De})_3_{(\text{ADP})_{3\text{cat},2\text{non-cat}}}$  is different from that of  $A_3(\text{De})_3_{(\text{ADP})_{3\text{cat},1\text{non-cat}}}$  in terms of  
135 nucleotide occupation at the designed site; these structures may provide the allosteric response upon  
136 ADP binding in the designed site (details are described later and in Fig. 5d).

137 **Creation of ATP binding sites at the non-catalytic interfaces impacts on the**  
138 **catalytic interfaces**

139 Fluorescence polarization measurements using the fluorescent-labeled AMP-PNP (Mant-AppNHp)  
140 and ADP (Mant-ADP), revealed that the nucleotide-binding affinities of the designed complex are  
141 much lower than those of the wild-type complex (Fig. 3a). The measured binding affinity of the  $A_3B_3$   
142 and  $A_3(\text{De})_3$  complexes respectively were  $14.5 \pm 5.7$  nM and  $2.03 \pm 0.18$   $\mu\text{M}$  for AMP-PNP, and  $64.2$   
143  $\pm 0.9$  nM and  $0.55 \pm 0.003$   $\mu\text{M}$  for ADP. Note that the affinities of  $A_3(\text{De})_3$ , measured in a range of  
144 relatively low nucleotide concentration, are expected for the first nucleotide binding to one of the  
145 catalytic interfaces, as supposed by the  $A_3(\text{De})_3_{\text{(ANP)}}_{1\text{cat}}$  structure, in which a single nucleotide was  
146 bound to one of the catalytic interfaces (Fig. 2b). Structure comparison of  $A_3(\text{De})_3_{\text{empty}}$  with the  
147 nucleotide-free wild-type  $A_3B_3$  provides an interpretation for the decreased affinities (Fig. 3b). The P-  
148 loops in the three A-subunits in the wild-type  $A_3B_3$  complex are classified into the two distinct  
149 conformations, bound and unbound forms (Supplementary Fig. 10). The P-loop in an A-subunit is  
150 the bound form and those in the other two A-subunits are the unbound form (Fig. 3b, top). The bound  
151 form is expected to have a higher binding affinity than the unbound form<sup>16</sup>. However, the P-loop  
152 conformations of all A-subunits in  $A_3(\text{De})_3_{\text{empty}}$  were found to be the unbound form, explaining the

153 lower affinities of the catalytic interface. In other words, the creation of ATP binding sites in the non-  
154 catalytic interfaces changed the conformations of the ATP binding sites in the catalytic interfaces.

155 **Creation of ATP binding sites induces global conformational change of the A<sub>3</sub>(De)<sub>3</sub>**  
156 **complex**

157 The comparison of the A<sub>3</sub>(De)<sub>3</sub>\_empty with the nucleotide-free wild-type complex revealed that  
158 conformational changes occurred not only in the P-loop of the A-subunits but also in the overall  
159 structure of the A-subunits (Fig. 3b, bottom), although remarkable conformational changes were not  
160 found in any of the B-subunits (the structures of  $\alpha$ -helical domains are locally different from the wild-  
161 type B-subunits due to their innate flexibility) (Fig. 3d). In the nucleotide-free wild-type complex, the  
162 A-subunit, of which the P-loop is the bound form, shows the closed conformation (the C-terminal  
163 domain bends toward the pore of the ring complex), and the other two A-subunits with the unbound  
164 form are in the open conformation<sup>16</sup>. However, all A-subunits in the design complex, A<sub>3</sub>(De)<sub>3</sub>\_empty,  
165 show the open conformation with the unbound form (Fig. 3b). Furthermore, these conformational  
166 changes broke the asymmetric arrangement of A- and B- subunits found in the wild-type ring  
167 complex<sup>16</sup>, resulting in a nearly symmetric arrangement with the expansion of the ring pore in the  
168 design complex (Fig. 3c). This observation leads to the hypothesis that the central rotor is difficult to  
169 retain in the expanded pore. As expected, the reconstitution experiments of the rotor (D- and F-  
170 subunits) and ring (A- and B- subunits) complex show that the reconstitution ratio was quite low  
171 (Supplementary Fig. 11). Interestingly, the conformational changes observed in A<sub>3</sub>(De)<sub>3</sub>\_empty were

172 almost reverted by a nucleotide binding at a catalytic interface, as observed in  $A_3(\text{De})_3_{\text{-(ANP)}}_{1\text{cat}}$   
173 (Supplementary Fig. 11), and the complex reconstitution ratio was also recovered in the presence of  
174 nucleotide (Supplementary Fig. 12). The detailed comparisons of  $A_3(\text{De})_3_{\text{empty}}$  and  
175  $A_3(\text{De})_3_{\text{-(ANP)}}_{1\text{cat}}$  with the nucleotide-free wild-type complex structure<sup>16</sup> are described in  
176 Supplementary Tables 1-4.

## 177 **The designed $V_1$ rotates faster than the wild-type**

178 Finally, we carried out single-molecule experiments to observe the rotation of the  $A_3(De)_3DF$   
179 complex in various ATP concentrations ( $[ATP]_s$ ). The designed  $V_1$  was found to rotate unidirectionally  
180 in a counterclockwise fashion with discrete  $120^\circ$  steps, similar to the wild-type, but rotates faster than  
181 the wild-type at  $100 \mu M$  ATP (Fig. 4a). Furthermore, in contrast to the wild-type, the rotation rate of  
182 the designed  $V_1$  exhibited an unique non-Michaelis-Menten type dependence on  $[ATP]$ . Rotation rates  
183 very similar to the wild-type were observed at the lowest ( $1 \mu M$ ) and the highest ( $30 mM$ )  $[ATP]$ , but  
184 the rotation was significantly accelerated in the range between the highest and lowest  $[ATP]_s$  (Fig. 4b,  
185 top). At  $100 \mu M$  ATP, the designed  $V_1$  showed the most accelerated rotation rate ( $115 \pm 17$  rps)  
186 compared with the wild-type ( $76 \pm 4.8$  rps). To the best of our knowledge, this is the first time that  
187 unidirectional movements of ATP-driven rotary molecular motors have been “overclocked” by protein  
188 engineering.

189 Furthermore, we found that the  $[ATP]$ , at which the designed  $V_1$  shows the maximal acceleration  
190 compared with the wild-type, can be tuned by modulating the nucleotide-binding affinity of the  
191 designed site (Fig 4b). The mutant K157Q at one of the conserved residues in P-loop motif in the  
192 designed site, expected to have a decreased binding affinity<sup>31</sup>, exhibited the non-Michaelis-Menten  
193 type rotation rate similar to the design, but notably, the  $[ATP]$ , at which the most accelerated rotation

194 was observed, shifted higher from that for the original design: 1 mM [ATP](Fig. 4b, middle). In  
195 addition, the double mutant K157A/S158A in the P-loop, which has a further decreased binding  
196 affinity (Note that the mutant is still expected to have a capability to bind ATP<sup>29</sup>), rotated in the similar  
197 fashion but the [ATP], at which the most accelerated rotation was observed, further shifted higher from  
198 that for the K157Q mutant: 3 mM [ATP] (Fig. 4b, bottom). Furthermore, the rotation rate at the ATP  
199 concentration was the highest ( $161 \pm 18$  rps) among those for the wild-type, the original design and  
200 the mutants (Fig. 4b). This observed correlation between the nucleotide binding affinity of the designed  
201 site and the [ATP] at which the most acceleration is observed strongly suggests the allosteric effect  
202 produced by the nucleotide-binding to the designed site.



## 203 **ADP-release at the catalytic site is facilitated allosterically**

204 In the 120° step rotation, the designed  $V_1$  was found to have the main-pauses and sub-pauses before  
205 the 40° and 80° sub-steps respectively, which is the same as the wild-type  $V_1$ <sup>28</sup> (Fig. 5a). To reveal the  
206 mechanism of allosteric acceleration, we carried out dwell-time analyses of the two pauses at the high  
207 and low [ATP] (1  $\mu$ M and 30 mM, respectively), in which the designed  $V_1$  rotated at a similar rate as  
208 the wild-type, and at the 100  $\mu$ M [ATP], in which the design exhibited the most accelerated rotation.  
209 In the proposed rotation model for the wild-type<sup>28</sup>, the main-pause corresponds to the dwell-time  
210 waiting for ATP-binding, ATP-hydrolysis, and Pi-release, and the sub-pause corresponds to that for  
211 ADP-release. The main-pause time constants of the design at each measured [ATP] are roughly the  
212 same as those of the wild-type, irrespective of [ATP] (Fig. 5b). The sub-pause time constants for the  
213 wild-type stayed constant between 2.1~2.7 ms, at any [ATP]s, and the time constants for the design at  
214 the low and high [ATP] are similar to those for the wild-type. However, the time constant at the [ATP]  
215 (100  $\mu$ M ATP), at which the designed  $V_1$  showed the most accelerated rate, significantly decreased to  
216 1.0 ms (Fig. 5b). The double mutant (K157A/S158A) also exhibited behavior similar to the original  
217 design, and the sub-pause time constant was drastically decreased to 0.6 ms at 3 mM ATP. The rotation  
218 rates estimated from the measured time constants for the main- and sub-pauses, agreed with the  
219 observed rotation rates shown in Fig. 4b (Supplementary Table 6). All these results indicate that the

220 origin of the acceleration is the facilitated ADP-release at the catalytic sites, which is generated through  
221 the allosteric effect triggered by nucleotides binding to the designed sites.

222 Structural comparisons between the solved structures,  $A_3(\text{De})_3_{\text{(ADP)}_{3\text{cat},1\text{non-cat}}}$  and  
223  $A_3(\text{De})_3_{\text{(ADP)}_{3\text{cat},2\text{non-cat}}}$ , provide a structure-based interpretation for ADP-release promoted by the  
224 allosteric effect, although these structures are bound not with ATP but ADP, and do not contain the  
225 rotor. An ATP-binding at the designed site is suggested to induce conformational changes of the  
226 neighboring A-subunit and the catalytic interface from the closed conformation to the open-like  
227 conformation (Fig. 5c,d and Supplementary Tables 7 and 8), which creates space to facilitate ADP  
228 release.

229 **Possible model of the rotation scheme for designed V<sub>1</sub>**

230 From the results described above, a rotation scheme for the designed V<sub>1</sub> is proposed based on the  
231 scheme for the wild-type recently proposed by Iida *et al.* (Fig. 5e, left)<sup>28</sup>. For the wild-type, two or  
232 three catalytic sites are occupied at any time with ATP or its product(s) of hydrolysis. ATP-binding to  
233 an empty catalytic site triggers a 40° sub-step, and the subsequent release of ADP from the neighbor  
234 catalytic-site generates the 80° sub-step. The design may rotate in a similar scheme except for the ATP-  
235 binding to one or two designed sites at the non-catalytic interfaces, which facilitates ADP-release in  
236 the neighboring catalytic site through an allosteric effect (Fig. 5e, right). It is obvious that the allosteric  
237 effect does not emerge at low [ATP] since the designed sites are not able to bind ATP due to low affinity,  
238 but it is still puzzling why the allosteric effect is not observed in high [ATP]; the full nucleotide  
239 occupation in the three designed sites may suppress the allosteric effect, but, this should be verified in  
240 the future.

## 241 **Implications to native $V_1$ -ATPase and a common mechanism for rotary motors**

242 The designed  $V_1$  not only exhibited the allosteric control over the rotation, but also provided possible  
243 designs and working principles for the native  $V_1$ -ATPase. It is suggested that ancestral  $V_1$ -ATPase  
244 existed as a homo hexameric ring, in which all subunits perform ATP binding and hydrolase functions,  
245 which has since evolved to form the current hetero hexameric ring containing the pseudo-enzyme  
246 subunit (B-subunit) that lost these functions<sup>20</sup>. Restoring ATP binding ability at the pseudo-active site  
247 may lead to an understanding of why the modern, descendant  $V_1$ -ATPase lost its ATP binding and  
248 hydrolase functions. First, it is plausible that the non-catalytic interface observed in the modern  $V_1$ -  
249 ATPase plays a role in attaining the Michaelis-Menten type rotation, in which the rotation rate is  
250 smoothly regulated along an [ATP] (Fig. 4b). The sudden increase and decrease of rotation rate at an  
251 [ATP] as observed in the designed  $V_1$  would not be preferable in terms of functional regulation by  
252 nature (this property can be beneficial for human since  $V_1$  can be engineered with the maximal rotation  
253 rate at an arbitrary [ATP]). Second, the non-catalytic interface may be a key factor for making the  
254 asymmetrical ring shape observed in the modern  $V_1$ -ATPase in the absence of nucleotides, as we  
255 observed that the designed  $V_1$  forms a nearly symmetric ring structure (Fig. 3b,c). The asymmetrical  
256 ring shape is considered to be one of the key factors to realize the unidirectional rotation<sup>16</sup> (it is reported  
257 that the N-terminal  $\beta$  barrel domains in the A- and B-subunits also play this role<sup>32</sup>). At the end, restoring

258 ATP binding ability also implies a common mechanism for hexameric rotary motors of  $V_1$  and  $F_1$ : the  
259 non-catalytic interface has the capability to provide allosteric control over ADP release at the  
260 neighboring catalytic interface, as observed in our design of  $V_1$  (Fig. 4b, and Fig. 5b,d) and the  
261 mutation of  $F_1$  described in the Introduction<sup>21</sup>.

262

## 263 **Conclusion**

264 We succeeded in programming allosteric control into the molecular motor  $V_1$ -ATPase by computational  
265 de novo design of a ATP binding site at the pseudo-active site in the non-catalytic interface of  $V_1$ .  
266 Furthermore, the artificially designed  $V_1$  provided implications for design and working principles of  
267 the native  $V_1$ -ATPase. Pseudo-enzymes are frequently found in native complex-forming proteins, e.g.  
268  $F_1$ -ATPase<sup>22</sup>, dynein<sup>33</sup>, kinesin<sup>34</sup>, 20S proteasome<sup>35</sup>, kinases<sup>13</sup> and plant resistosome<sup>36</sup>. Engineering  
269 pseudo-active sites could be one of the promising approaches for de novo design of allosteric control  
270 into complex-forming proteins.

## 271 **Methods**

### 272 **Computational design protocol**

273 The B-subunit was computationally redesigned using the structure, chain E in PDB 3VR6. First, the  
274 pseudo P-loop in B-subunit (the residues 151-158) were replaced by the P-loop motif of A-subunit (the  
275 residues 232-239), by superimposing the A-subunit (chain B in the same PDB 3VR6) to the B-subunit  
276 with the orientation feature of P-loop shown in Supplementary Fig. 3a. Second, ATP binding modes  
277 were designed using Rosetta design software<sup>37</sup> with Talaris2014 score function (Parameters for ATP-  
278 Mg<sup>2+</sup> were determined using those for atom types already defined in Rosetta). In the design calculation,  
279 side-chain conformations for the residue positions of the P-loop and the surrounding residues (E169,  
280 T248, Q339, and F417), having favorable interactions with ATP, were explored with various ATP  
281 conformations generated by BCL software<sup>38</sup> and with the distance constraints between the atoms of P-  
282 loop and the phosphate atoms of ATP (Supplementary Fig. 3d) (the amino acid at X<sub>3</sub> in P-loop was  
283 fixed to Gly (Supplementary Fig. 3c)). Third, the designed B-subunit structures with ATP were  
284 minimized. The second and third steps were iterated 20 times and 800 different ATP binding modes  
285 were designed. Fourth, the designed structures that lost the feature for conserved backbone torsion  
286 pattern of P-loop (Supplementary Fig. 3b) were abandoned, and then those of which ATP binding score  
287 (Rosetta ddG score) are less than -8.0 were finally selected (29 designs).

## 288 **Molecular dynamics simulations**

289 The 29 designs obtained by the computational design using Rosetta was further evaluated for their  
290 ATP binding ability by observing the stability of ATP in the designed site during short molecular  
291 dynamics (MD) simulations. The AMBER14 software suite<sup>39</sup> was used for all MD simulations. The  
292 design models were used as the initial structures, of which hydrogen atoms were added by the LEaP  
293 module of AMBER14<sup>39</sup>. The simulation system contains a designed B-subunit monomer with ATP  
294 placed in a water box of approximately  $82 \text{ \AA} \times 112 \text{ \AA} \times 100 \text{ \AA}$ . To neutralize the system, 15-17 sodium  
295 ions were put in the box. AMBER ff99SB sets and TIP3P were utilized for the protein and water  
296 molecules, respectively. Parameters for ATP molecule were adopted from a reference paper<sup>40</sup>. Long  
297 range electrostatic interactions were treated by the particle mesh Ewald (PME) method. Non-bonded  
298 interactions were cut off at  $10 \text{ \AA}$ . After carrying out a short minimization to remove artificial repulsions  
299 in the initial structure, 10 ns MD simulations in a constant-NPT (300K, 1atm) ensemble were  
300 performed after the 100 ps heating stage with NVT ensemble (the time step is 2.0 fs and hydrogen  
301 atoms were constrained with SHAKE procedure). At the heating step, the temperature was raised  
302 gradually from 0 K to 300 K with the weak restraints ( $10 \text{ kcal/mol/\AA}^2$ ) to the atoms of designed B-  
303 subunit. The MD simulation trajectory for each designed structure are shown in Supplementary Fig. 6  
304 with the root mean square deviation (RMSD) values for the heavy atoms of ATP molecule from the



305 minimized structure. Finally, a designed structure showing low RMSD value throughout the MD  
306 simulation was selected for experimental characterization.

## 307 **Expression and purification of the A<sub>3</sub>(De)<sub>3</sub> Complex**

308 A DNA fragment of the design was synthesized from the *ntpB* gene in pTR19-AB<sup>28</sup> using megaprimer  
309 PCR method, and then the *ntpB* gene was replaced by this design fragment. The DNA sequence of  
310 design plasmid was confirmed by DNA sequencing analysis (Fasmac). *E. coli*. BL21\* (DE3)  
311 competent cells were transformed with the plasmid and cultured at 30 °C for 20 hours in Super Broth  
312 (32 g/L Tryptone, 20 g/L yeast extract and 5 g/L sodium chloride) containing 100 µg/mL ampicillin  
313 and 2 mM isopropyl β-D-thiogalactopyranoside. Grown cells were spun down at 6,000 rpm for 10  
314 minutes and washed twice with buffer A (20 mM potassium P<sub>i</sub> (pH 7.0) and 100 mM NaCl). The cells  
315 were suspended in 15 mL of buffer A supplemented with 75 µL 100 mM phenylmethylsulfonyl fluoride  
316 (PMSF) solution and subsequently disrupted by sonication. After removing cell debris by  
317 centrifugation at 10,000 rpm for 20 minutes at 4 °C, the solution was filtered and applied to a Ni-NTA  
318 column. After washing with buffer B (20 mM potassium P<sub>i</sub> (pH 7.0), 230 mM NaCl and 20 mM  
319 Imidazole), A<sub>3</sub>(De)<sub>3</sub> complex was eluted with buffer C (20 mM potassium P<sub>i</sub> (pH 7.0), 50 mM NaCl  
320 and 250mM Imidazole). The eluted fractions were concentrated with a Vivaspin20 5,000 MWCO  
321 (Sartorius) and then passed through a Superdex 200 Increase column (GE Helthcare) equilibrated with  
322 buffer D (20 mM MES-NaOH (pH 6.5), 100 mM KCl, 5 mM MgSO<sub>4</sub>, 0.1 mM DTT and 10% glycerol).  
323 The purified proteins were stored at -80 °C. The above described methods were also used for

324 expression and purification of the wild-type A<sub>3</sub>B<sub>3</sub> complex.

325

## 326 **Expression and purification of the design monomer**

327 The designed B-subunit monomer was obtained by breaking the  $A_3(De)_3$  complex sample in the  
328 presence of high concentration ATP. After expression and Ni-NTA purification of the  $A_3(De)_3$  complex  
329 sample by the above described methods, the buffer of the  $A_3(De)_3$  sample solution eluted from a Ni-  
330 NTA column was exchanged to buffer E (20 mM MES-NaOH (pH 6.5), 10% Glycerol, 100 mM KCl  
331 and 5 mM  $MgSO_4$ ) using PD-10 column (GE Helthcare). The sample solution mixed with 2 mM ATP  
332 was rocked for 30-40 minutes at 4 °C, filtered and applied to a Ni-NTA column. Because A-subunit  
333 has a His-tag and designed B-subunit does not, designed B-subunit can be selectively recovered in the  
334 flow through. In the flow through sample, Tris-HCl was added (100 mM final concentration; pH 8.5).  
335 The buffer of sample solution was exchanged to buffer F (20 mM Tris-HCl (pH 8.5), 10% Glycerol,  
336 100 mM KCl and 5 mM  $MgSO_4$ ) by concentrating with a Vivaspin20 5,000 MWCO (Sartorius) and  
337 adding buffer F. The samples were passed through a Superdex 200 Increase column (GE Helthcare)  
338 equilibrated with buffer F. The purity of design monomer sample was confirmed by SDS-PAGE  
339 (Supplementary Fig. 7c).

## 340 **Expression and purification of the wild-type B-subunit**

341 The wild-type B-subunit monomer was expressed with pTR19-B plasmid, which is constructed from  
342 the pTR19-AB plasmid<sup>28</sup> by deleting the *ntpA* gene and adding His-tag to the *ntpB* gene, using the  
343 same protocol used for the A<sub>3</sub>(De)<sub>3</sub> complex. The cells were suspended in 25 mL of buffer G (20 mM  
344 Tris-HCl (pH 8.5), 5% Glycerol, 0.7 M KCl, 5 mM MgSO<sub>4</sub>, 0.1 mM DTT and 20 mM Imidazole  
345 (pH8.5)) supplemented with 125 μL of 100 mM PMSF solution, and then disrupted by sonication.  
346 After removing cell debris by centrifugation at 10,000 rpm for 20 minutes at 4 °C, the solution was  
347 filtered and applied to a Ni-NTA column. After washing with buffer H (20 mM Tris-HCl (pH 8.5), 5%  
348 Glycerol, 0.7 M KCl, 5 mM MgSO<sub>4</sub>, 0.1 mM DTT and 20 mM Imidazole (pH8.5)), B-subunit  
349 monomer was eluted with buffer I (20 mM Tris-HCl (pH 8.5), 5% Glycerol, 0.7 M KCl, 5 mM MgSO<sub>4</sub>,  
350 0.1 mM DTT and 250 mM Imidazole (pH8.5)). The eluted fractions were concentrated with a  
351 Vivaspin20 5,000 MWCO (Sartorius) and then passed through a Superdex 200 Increase column (GE  
352 Helthcare) equilibrated with buffer F. The purified proteins were stored at -80 °C.

## 353 **Expression and purification of the DF-subcomplex**

354 The DF-subcomplex of *Enterococcus hirae* V<sub>1</sub> were expressed in *E. coli*. BL21\* (DE3) competent  
355 cells using the pTR19-D(M1G/T60C/R131C)F plasmid<sup>28</sup>. The transformed cells were cultured in  
356 Super Broth containing 100 µg/ml ampicillin at 37°C for 4-5 hours until OD<sub>600</sub> reached 0.5, then the  
357 temperature was decreased to 30 °C and expression of DF-subcomplex was induced by the addition of  
358 2 mM isopropyl β-D-thiogalactopyranoside. Cells were harvested 20 hours after induction by  
359 centrifugation at 6,000 rpm for 10 minutes. The cells were suspended in 20 mL of buffer J (20 mM  
360 potassium P<sub>i</sub> (pH 8.0), 300 mM NaCl and 20 mM Imidazole) supplemented with 100 µL of 100 mM  
361 PMSF solution, and then disrupted by sonication. After removal of cell debris by centrifugation at  
362 10,000 rpm for 20 minutes at 4 °C, the solution was filtered and applied to a Ni-NTA column. After  
363 washing with buffer J, DF-subcomplex was eluted with buffer K (20 mM potassium P<sub>i</sub> (pH 8.0), 300  
364 mM NaCl and 500 mM Imidazole). The eluted sample and TEV protease were mixed in 10:1 molar  
365 ratio and dialyzed against buffer L (20 mM potassium P<sub>i</sub> (pH8.0), 50 mM NaCl, and 1 mM DTT)  
366 overnight. The dialyzed sample was spun down at 10,000 rpm for 20 minutes at 4 °C, and then applied  
367 to PD10 column for changing the buffer to buffer J. The eluted sample was applied to a Ni-NTA column  
368 and the flow thorough was collected. After adding 1 mM DTT, the sample was concentrated with a  
369 Vivaspin20 5,000 MWCO (Sartorius) and then passed through a Superdex 75 column (GE Helthcare)

370 equilibrated with buffer M (20 mM Tris-HCl (pH 8.0), 150 mM NaCl). The purified proteins were  
371 stored at -80 °C. For single-molecule experiments, the cysteine residues introduced in D-subunit by  
372 the mutations T60C and R131C were biotinylated using the purified DF-subcomplex sample. The  
373 buffer of sample solution was changed to buffer N (20 mM potassium P<sub>i</sub> (pH7.0), 150 mM NaCl) using  
374 PD10 column. The biotinylation reagent (biotin-PEAC<sub>5</sub>-maleimide, Dojindo) was mixed into the  
375 purified DF-subcomplex sample solution with 3:1 molar ratio, and then incubated for 30 minutes at  
376 room temperature. Finally, DTT (10 mM final concentration) was added to the sample solution and  
377 the sample was stored at -80 °C. The purification results for gel filtration and SDS-PAGE are shown  
378 in Supplementary Fig. 7d.

## 379 **Expression and purification of the A<sub>3</sub>(De)<sub>3</sub> for crystallization**

380 The A<sub>3</sub>(De)<sub>3</sub> protein sample for crystallization were prepared by cleaving the His-tag attached to the  
381 N-terminal of A-subunit. TEV protease cleavage site was inserted between the *ntpA* gene and His-tag  
382 in pTR19-AB<sup>28</sup> by KOD-Plus-Mutagenesis Kit (TOYOBO). With this plasmid, the A<sub>3</sub>(De)<sub>3</sub> sample  
383 was expressed and purified by using Ni-NTA column in the same protocol described above. The eluted  
384 sample and TEV protease were mixed in 10:1 molar ratio and dialyzed against buffer O (20 mM Tris-  
385 HCl (pH8.0) and 50 mM NaCl). This dialyzed samples were applied to a Ni-NTA column and the flow  
386 through was collected. Then, the sample was loaded onto a HiTrap Q HP column (GE Healthcare Life  
387 Sciences) equilibrated with buffer O, and then eluted with a linear gradient of buffer O with 50-1,000  
388 mM NaCl in 20 min at flow rate of 1.0 ml min<sup>-1</sup>. The concentrated sample with a Vivaspin20 5,000  
389 MWCO (Sartorius) was loaded onto a Superdex 200 Increase 10/300 GL column (GE Healthcare)  
390 equilibrated with buffer P (20 mM Tris-HCl (pH8.0), 150 mM NaCl and 2 mM DTT) at a flow rate of  
391 0.5 ml min<sup>-1</sup>. The purified sample were concentrated with a Vivaspin500 5,000 MWCO.



392 **Preparation of the design mutants**

393 The mutations were introduced by Quick Change Multi Site-Directed Mutagenesis Kit (Agilent  
394 Technologies). The purification and expression were carried out with the same method as the original  
395 design. The DNA sequence were confirmed by DNA sequencing analysis (Fasmac).

396

397

398 **Circular Dichroism measurement**

399 Thermal denaturation experiments for the designed B-subunit and the wild-type B-subunit were  
400 carried out by using the Circular Dichroism spectrometer, J-1500KS (JASCO). Far-ultraviolet circular  
401 dichroism spectra at 220 nm along the increase of temperature in steps of 1.0 °C/min with 60 s of  
402 equilibration time were collected for 5 µM protein samples in buffer F in a 1-cm-path-length cuvette.  
403 The measurements were carried out in the absence of nucleotides or in the presence of 1 mM ADP, 1  
404 mM ATP and 5 mM ATP after the incubation of the mixed solutions for 1 hour at 4 °C.

405 **Fluorescence polarization measurement for evaluating nucleotide-binding affinity**  
406 **of the A<sub>3</sub>(De)<sub>3</sub> complex**

407 Fluorescence polarization-based affinity measurements for the wild-type A<sub>3</sub>B<sub>3</sub> complex and the  
408 designed A<sub>3</sub>(De)<sub>3</sub> complex were performed using the fluorescent-labeled nucleotides, Mant-ADP and  
409 Mant-AppNHp (Jena Bioscience), in 100 nM. The changes in fluorescence anisotropy (*r*) of the  
410 fluorescent-labeled nucleotides mixed with the protein samples in Greiner black flat bottom 96 well  
411 plates, against the increase of the protein concentrations, were observed after 1 hour equilibration at  
412 room temperature on a Spark 10M (TECAN) using 360 nm excitation and 465 nm emission filters  
413 with 35 nm bandwidth filters. Buffer D was used for all measurement. Equilibrium dissociation  
414 constants (*K<sub>d</sub>*) were determined by the fitting to eq 1 with the anisotropy plots averaged over period of  
415 10 min (20 measurements), where *A* is the experimentally measured anisotropy, *A<sub>f</sub>* is anisotropy of the  
416 free ligand, *A<sub>b</sub>* is the anisotropy of the fully bound ligand, [*L*]<sub>T</sub> is the total ligand concentration, and  
417 [*R*]<sub>T</sub> is the total protein concentration. The *K<sub>d</sub>* values were determined by averaging the values from  
418 three independent measurements.

419 
$$A = A_f + (A_b - A_f) * \left( \frac{([L]_T + K_D + [R]_T) - \sqrt{(-[L]_T - K_D - [R]_T)^2 - 4[L]_T[R]_T}}{2[L]_T} \right) \quad \text{eq 1}$$

420 Note that the measured nucleotide affinities of the wild-type A<sub>3</sub>B<sub>3</sub> complex are possibly  
421 underestimated by the binding at the second catalytic site, since the 100 nM nucleotide concentration,

422 which is required to detect the fluorescence polarization of Mant, is not low enough against the binding  
423 affinity.

424 **Reconstitution experiments of the A<sub>3</sub>(De)<sub>3</sub>DF complex from the A<sub>3</sub>(De)<sub>3</sub> complex**  
425 **and the DF-subcomplex**

426 The A<sub>3</sub>(De)<sub>3</sub>DF complex was reconstituted from the A<sub>3</sub>(De)<sub>3</sub> complex and the DF-subcomplex. The  
427 purified A<sub>3</sub>(De)<sub>3</sub> and DF were mixed in a 1:5 molar ratio with the addition of MES-NaOH (pH6.0, 100  
428 mM final concentration) and incubated for 2 hour at room temperature in the presence or absence of  
429 20 μM AMP-PNP or ADP. The samples were filtered and passed through a Superdex 200 Increase  
430 column (GE Helthcare) equilibrated with buffer Q (20 mM MES-NaOH (pH 6.5), 10% Glycerol, 100  
431 mM NaCl, 5 mM MgSO<sub>4</sub> and 2 mM DTT). The reconstitution rate shown in Supplementary Fig. 11  
432 was evaluated by SDS-PAGE for 1.5 μM, 14 μL of purified samples mixed with Tris-Glycine SDS  
433 buffer, and then quantified by ImageJ<sup>41</sup> using eq 2, where A<sub>WT</sub>, A<sub>Design</sub> are the optical densities of A-  
434 subunit in the wild-type complex or in the design complex, respectively, and D<sub>WT</sub> and D<sub>Design</sub> are those  
435 of D-subunit.

436 
$$\left( A_{WT} / A_{Design} \right) \times D_{Design} / D_{WT} \quad \text{eq 2}$$

437

## 438 **Crystallization, data collection and structure determination**

439 The sitting drop vapor diffusion method was used for crystallization. Crystals for  $A_3(\text{De})_3\_empty$   
440 were obtained by mixing 2.0  $\mu\text{L}$  protein solution drop (10-15 mg/mL protein in buffer P) with 2.0  $\mu\text{L}$   
441 of reservoir solution (0.1 M Tris-HCl (pH 8.5), 20-24% PEG 3350 and 0.2 M Ammonium Acetate).  
442 The crystals were appeared in 1-2 weeks at 293K. The crystals were soaked in cryo-protectant  
443 solutions with an increasing concentration of 10% (v/v) glycerol. For  $A_3(\text{De})_3\_(\text{ANP})_{1cat}$ ,  
444  $A_3(\text{De})_3\_empty$  crystals were soaked for 5 hours in 20  $\mu\text{M}$  AMP-PNP, 200  $\mu\text{M}$   $\text{MgSO}_4$  and 10%  
445 glycerol. For  $A_3(\text{De})_3\_(\text{ADP}\cdot\text{Pi})_{1cat}(\text{ADP})_{2cat,2non-cat}$ ,  $A_3(\text{De})_3\_empty$  crystals were soaked to ADP,  
446  $\text{MgCl}_2$  and glycerol for 5 hours by gradually increasing the concentration to 10 mM, 10 mM and 10%,  
447 respectively. For  $A_3(\text{De})_3\_(\text{ADP})_{3cat,1non-cat}$  and  $A_3(\text{De})_3\_(\text{ADP})_{3cat,2non-cat}$ ,  $A_3(\text{De})_3\_empty$  crystals were  
448 soaked to ADP,  $\text{MgCl}_2$  and glycerol overnight by gradually increasing the concentration to 5 mM, 5  
449 mM and 10%, respectively.

450 The crystals were mounted on cryo-loops (Hampton Research), flash-cooled and stored in liquid  
451 nitrogen. All X-ray diffraction data were collected at the wavelength 1.1  $\text{\AA}$  on beamline BL-1A at  
452 Photon Factory (Tsukuba, Japan), from a single crystal at the cryogenic temperature (100K). The  
453 collected data were processed by using XDS<sup>42</sup>. The structure of  $A_3(\text{De})_3\_empty$  and  $A_3(\text{De})_3$  with  
454 nucleotides were determined by molecular replacement method with Phaser<sup>43</sup> using  $A_3B_3$  complex

455 from *Enterococcus hirae* (PDB 3VR2) and obtained A<sub>3</sub>(De)<sub>3</sub>\_empty structure as a search model,  
456 respectively. The initial model was iteratively refined with PHENIX<sup>44</sup> and REFMAC5(CCP4 Suite)<sup>45</sup>  
457 and manually corrected with COOT<sup>46</sup>. Figures are prepared by PyMOL<sup>47</sup>, CueMol<sup>48</sup> and Chimera<sup>49</sup>.  
458 The crystallographic and refinement statistics are summarized in Supplementary Table 9.

## 459 **Single-molecule experiments of the designed V<sub>1</sub>-ATPase**

460 The protein sample was prepared by mixing the purified A<sub>3</sub>(De)<sub>3</sub> and the biotinylated DF-subcomplex  
461 in a 1:5 molar ratio with the addition of MES-NaOH (pH6.0, 100mM final concentration), followed  
462 by the incubation in the presence of 200 μM ADP for 2 hours at room temperature. The sample was  
463 filtered and passed through a Superdex 200 Increase column (GE Helthcare) equilibrated with buffer  
464 Q and were concentrated to few μM with a Vivaspin500 5,000 MWCO. The samples were stored at -  
465 80 °C.

466 Single-molecule experiments were carried out by the method reported in the paper<sup>28</sup>. The flow cell  
467 was prepared by covering an untreated coverglass (18 × 18 mm<sup>2</sup>, Matsunami Glass) on a coverglass  
468 (24 × 32 mm<sup>2</sup>, Matsunami Glass) treated by overnight immersion in piranha solution (H<sub>2</sub>SO<sub>4</sub>/H<sub>2</sub>O<sub>2</sub> =  
469 3:1). After capturing the protein sample on the treated coverglass by His-tag, the streptavidin-coated  
470 40-nm gold nanoparticle was attached to the biotinylated DF. The rotation of gold nanoparticle was  
471 observed by using an objective-type total internal reflection dark-field microscope<sup>50</sup> constructed on an  
472 inverted microscope (IX-70, Olympus). The gold nanoparticles were illuminated by the evanescent  
473 field with the penetration depth of 100 nm from the glass surface. The scattered image of a rotating  
474 gold nanoparticle was recorded as a movie with a high-speed CMOS camera (FASTCAM 1024PCI,  
475 Photron) at 10,000 frames per second (fps) for almost all samples and at 27,000 fps for dwell time

476 analyses of the double mutant at 3 mM ATP. During observation and recording under the microscope,  
477 ATP-regeneration system, in which ADP is rapidly regenerated to ATP by the coupling with  
478 dephosphorylation of phosphoenolpyruvate catalyzed by pyruvate kinase, was used to keep ATP  
479 concentration constant.



480

## References

481

1. Gavin, A.-C. et al. Proteome survey reveals modularity of the yeast cell machinery. *Nature* **440**, 631-636 (2006).

482

483

2. Alberts, B. The Cell as a Collection of Protein Machines: Preparing the Next Generation of Molecular Biologists. *Cell* **92**, 291-294 (1998).

484

485

3. Kuriyan, J. & Eisenberg, D. The origin of protein interactions and allostery in colocalization. *Nature* **450**, 983-990 (2007).

486

487

4. Makhlynets, O.V., Raymond, E.A. & Korendovych, I.V. Design of Allosterically Regulated Protein Catalysts. *Biochemistry* **54**, 1444-1456 (2015).

488

489

5. Liu, H. et al. Control of a biomolecular motor-powered nanodevice with an engineered chemical switch. *Nature Materials* **1**, 173-177 (2002).

490

491

6. Lee, J. et al. Surface Sites for Engineering Allosteric Control in Proteins. *Science* **322**, 438 (2008).

492

493

7. Feng, J. et al. A general strategy to construct small molecule biosensors in eukaryotes. *eLife* **4**, e10606 (2015).

494

495

8. Nakamura, M. et al. Remote control of myosin and kinesin motors using light-activated gearshifting. *Nature Nanotechnology* **9**, 693 (2014).

496

497

9. Cosentino, C. et al. Engineering of a light-gated potassium channel. *Science* **348**, 707 (2015).

498

499

10. Zeqiraj, E. & van Aalten, D.M. Pseudokinases-remnants of evolution or key allosteric regulators? *Curr Opin Struct Biol* **20**, 772-81 (2010).

500

501

11. Ribeiro, A.J.M. et al. Emerging concepts in pseudoenzyme classification, evolution, and signaling. *Science Signaling* **12**, eaat9797 (2019).

502

503

12. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The Protein Kinase Complement of the Human Genome. *Science* **298**, 1912 (2002).

504

505

13. Zeqiraj, E., Filippi, B.M., Deak, M., Alessi, D.R. & van Aalten, D.M.F. Structure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation. *Science* **326**, 1707 (2009).

506

507

14. Rajakulendran, T. & Sicheri, F. Allosteric Protein Kinase Regulation by Pseudokinases: Insights from STRAD. *Science Signaling* **3**, pe8 (2010).

508

509

15. Marshansky, V. & Futai, M. The V-type H<sup>+</sup>-ATPase in vesicular trafficking: targeting, regulation and function. *Curr Opin Cell Biol* **20**, 415-26 (2008).

510

511

16. Arai, S. et al. Rotation mechanism of *Enterococcus hirae* V1-ATPase based on asymmetric crystal structures. *Nature* **493**, 703-7 (2013).

512

513

17. Arai, S. et al. Reconstitution in vitro of the catalytic portion (NtpA3-B3-D-G complex) of

- 514 Enterococcus hirae V-type Na<sup>+</sup>-ATPase. *Biochem Biophys Res Commun* **390**, 698-702 (2009).
- 515 18. Liu, Q., Kane, P.M., Newman, P.R. & Forgac, M. Site-directed mutagenesis of the yeast V-  
516 ATPase B subunit (Vma2p). *J Biol Chem* **271**, 2018-22 (1996).
- 517 19. Vasilyeva, E., Liu, Q., MacLeod, K.J., Baleja, J.D. & Forgac, M. Cysteine scanning  
518 mutagenesis of the noncatalytic nucleotide binding site of the yeast V-ATPase. *J Biol Chem*  
519 **275**, 255-60 (2000).
- 520 20. Mulkidjanian, A.Y., Makarova, K.S., Galperin, M.Y. & Koonin, E.V. Inventing the dynamo  
521 machine: the evolution of the F-type and V-type ATPases. *Nat Rev Microbiol* **5**, 892-9 (2007).
- 522 21. Matsui, T. et al. Catalytic activity of the  $\alpha\beta\gamma$  complex of F1-ATPase without noncatalytic  
523 nucleotide binding site. *J Biol Chem* **272**, 8215-21 (1997).
- 524 22. Walker, J.E. ATP Synthesis by Rotary Catalysis (Nobel lecture). *Angew Chem Int Ed Engl* **37**,  
525 2308-2319 (1998).
- 526 23. Walker, J.E., Saraste, M., Runswick, M.J. & Gay, N.J. Distantly related sequences in the alpha-  
527 and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a  
528 common nucleotide binding fold. *The EMBO journal* **1**, 945-951 (1982).
- 529 24. Saraste, M., Sibbald, P.R. & Wittinghofer, A. The P-loop--a common motif in ATP- and GTP-  
530 binding proteins. *Trends Biochem Sci* **15**, 430-4 (1990).
- 531 25. Tinberg, C.E. et al. Computational design of ligand-binding proteins with high affinity and  
532 selectivity. *Nature* **501**, 212-216 (2013).
- 533 26. Dou, J. et al. De novo design of a fluorescence-activating beta-barrel. *Nature* **561**, 485-491  
534 (2018).
- 535 27. Bick, M.J. et al. Computational design of environmental sensors for the potent opioid fentanyl.  
536 *eLife* **6**, e28909 (2017).
- 537 28. Iida, T. et al. Single-molecule analysis reveals rotational substeps and chemo-mechanical  
538 coupling scheme of Enterococcus hirae V1-ATPase. *J Biol Chem* **294**, 17017-17030 (2019).
- 539 29. Imamura, H., Funamoto, S., Yoshida, M. & Yokoyama, K. Reconstitution in vitro of V1  
540 complex of Thermus thermophilus V-ATPase revealed that ATP binding to the A subunit is  
541 crucial for V1 formation. *J Biol Chem* **281**, 38582-91 (2006).
- 542 30. Greenfield, N.J. Using circular dichroism collected as a function of temperature to determine  
543 the thermodynamics of protein unfolding and binding interactions. *Nat Protoc* **1**, 2527-35  
544 (2006).
- 545 31. Parsonage, D., Al-Shawi, M.K. & Senior, A.E. Directed mutations of the strongly conserved  
546 lysine 155 in the catalytic nucleotide-binding domain of beta-subunit of F1-ATPase from  
547 Escherichia coli. *J Biol Chem* **263**, 4740-4 (1988).
- 548 32. Maruyama, S. et al. Metastable asymmetrical structure of a shaftless V1 motor. *Science*

- 549 *Advances* **5**, eaau8149 (2019).
- 550 33. Kon, T. et al. The 2.8 Å crystal structure of the dynein motor domain. *Nature* **484**, 345-50  
551 (2012).
- 552 34. Allingham, J.S., Sproul, L.R., Rayment, I. & Gilbert, S.P. Vik1 Modulates Microtubule-Kar3  
553 Interactions through a Motor Domain that Lacks an Active Site. *Cell* **128**, 1161-1172 (2007).
- 554 35. Stadtmueller, B.M. & Hill, C.P. Proteasome Activators. *Molecular Cell* **41**, 8-19 (2011).
- 555 36. Wang, J. et al. Ligand-triggered allosteric ADP release primes a plant NLR complex. *Science*  
556 **364**, eaav5868 (2019).
- 557 37. Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and  
558 design of macromolecules. *Methods Enzymol* **487**, 545-74 (2011).
- 559 38. Kothiwale, S., Mendenhall, J.L. & Meiler, J. BCL::Conf: small molecule conformational  
560 sampling using a knowledge based rotamer library. *J Cheminform* **7**, 47 (2015).
- 561 39. D.A. Case, V.B., J.T. Berryman, R.M. Betz, Q. Cai, D.S. Cerutti, T.E. Cheatham, III, T.A.  
562 Darden, R.E. Duke, H. Gohlke, A.W. Goetz, S. Gusarov, N. Homeyer, P. Janowski, J. Kaus, I.  
563 Kolossváry, A. Kovalenko, T.S. Lee, S. LeGrand, T. Luchko, R. Luo, B. Madej, K.M. Merz, F.  
564 Paesani, D.R. Roe, A. Roitberg, C. Sagui, R. Salomon-Ferrer, G. Seabra, C.L. Simmerling, W.  
565 Smith, J. Swails, R.C. Walker, J. Wang, R.M. Wolf, X. Wu and P.A. Kollman. AMBER 14.  
566 (University of California, San Francisco., 2014).
- 567 40. Meagher, K.L., Redman, L.T. & Carlson, H.A. Development of polyphosphate parameters for  
568 use with the AMBER force field. *Journal of Computational Chemistry* **24**, 1016-1025 (2003).
- 569 41. Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. NIH Image to ImageJ: 25 years of image  
570 analysis. *Nature Methods* **9**, 671-675 (2012).
- 571 42. Kabsch, W. XDS. *Acta Crystallographica Section D* **66**, 125-132 (2010).
- 572 43. McCoy, A.J. et al. Phaser crystallographic software. *Journal of Applied Crystallography* **40**,  
573 658-674 (2007).
- 574 44. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular  
575 structure solution. *Acta Crystallographica Section D* **66**, 213-221 (2010).
- 576 45. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refinement of Macromolecular Structures by  
577 the Maximum-Likelihood Method. *Acta Crystallographica Section D* **53**, 240-255 (1997).
- 578 46. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. *Acta*  
579 *Crystallographica Section D* **66**, 486-501 (2010).
- 580 47. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 2.1. (2018).
- 581 48. CueMol: Molecular Visualization Framework (<http://www.cuemol.org/>).
- 582 49. Pettersen, E.F. et al. UCSF Chimera—A visualization system for exploratory research and  
583 analysis. *Journal of Computational Chemistry* **25**, 1605-1612 (2004).

- 584 50. Ueno, H. et al. Simple Dark-Field Microscopy with Nanometer Spatial Precision and  
585 Microsecond Temporal Resolution. *Biophysical Journal* **98**, 2014-2023 (2010).

586

## 587 **Acknowledgement**

588 We thank Prof. T. Murata at Chiba University for helpful suggestions; Dr. M. Kondo at ExCELLS  
589 and Dr. F. Kawai at Yamagata University for discussion about protein expression and purification; Dr.  
590 H. Ueno and Dr. Y. Minagawa at the University of Tokyo for advice about single-molecule  
591 experiments; Prof. T. Kinoshita at Osaka Prefecture University for discussion about pseudo-kinases;  
592 Prof. S. Akiyama at the Institute for Molecular Science and Prof. S. Takada at Kyoto University for  
593 comments on the manuscript; and Dr. R. Koga at ExCELLS for general discussion. We thank the  
594 Research Center for Computational Science (RCCS), Okazaki, Japan for providing its computational  
595 resources; the staff at the Photon Factory (PF) at KEK for assistance in synchrotron experiments and  
596 data collection for crystallographic analyses under the approval of PF program advisory committee  
597 (Proposal No. 2017G141); and for the support of the Basis for Supporting Innovative Drug Discovery  
598 and Life Science Research (BINDS) from AMED under Grant Number JP20am0101071 (supporting  
599 number BINDS0471). This work was supported by a Grant-in-Aid for Scientific Research on  
600 Innovative Areas “Molecular Engine” (JSPS KAKENHI Grant Number 18H05420 to T. K. and N. K.  
601 and 18H05424 to R. I.), by the National Institute for Natural Sciences (NINS), Okazaki Institute for  
602 Integrative Bioscience (Orion Project Grant Number 10341630611 to T.K. N. K. and R. I.), and by the  
603 Japan Science and Technology Agency (JST) Precursory Research for Embryonic Science and

604 Technology (PRESTO, Grant Number JPMJPR13AD to N. K.).

605

## 606 **Author Contributions**

607 T. K., R. I. and N. K. designed the research; T. K. computationally designed the ATP binding site; T.  
608 K. expressed and purified protein samples; T. K. performed biochemical measurements; T. K. and M.  
609 T. performed crystallography experiments and analyzed the data; T. K. and T. I. performed single-  
610 molecule experiments and analyzed the data; T. K. and N. K. wrote the manuscript; and T. K.  
611 coordinated the overall research. All authors discussed the results and commented on the manuscript.

612


## 613 **Competing financial interests**

614 The authors declare no competing financial interests.

615

## 616 **Additional Information**

617 **Supplementary Information** is available for this paper.



618

619 **Fig. 1. De Novo Design of an allosteric (ATP binding) site at the pseudo-active site of V<sub>1</sub>-ATPase.**

620 **a**, Strategy to de novo design of allosteric control into protein complexes by engineering the pseudo-

621 active site. **b**, Overview of design scheme. Left: Catalytic and non-catalytic interfaces, indicated by

622 solid and dotted arrows respectively, in the hexameric ring of V<sub>1</sub> consisting of A-subunits (cyan) and

623 their pseudo-enzyme B-subunits (salmon pink). The rotor of the D- and F- subunits (gray) is located

624 in the center of the ring. Middle: The structures of A- and B-subunits with the active and pseudo-active

625 sites, respectively. Right: An ATP binding site created at the pseudo-active site using the protein design

626 software Rosetta; gray color residues were selected for the design (11 residue positions). The residues

627 changed from the original sequence by the design are denoted with characters: the P-loop for binding

628 to the phosphate group of ATP was built at the residue positions 151-158 with the amino acid sequence,


629 GPPGAGKS; the Walker-B motif coordinating magnesium ion was built with glutamic acid at the

630 residue position 248; the nucleotide-binding pocket was made with the alanine at 159, creating space

631 for the binding of the sugar group of ATP (originally glutamic acid), and serine 339, making a hydrogen

632 bond with the adenine ring.





633

634 **Fig. 2. Solved five crystal structures of the  $A_3(De)_3$  complex in various conditions.**

635 The presented structures are viewed from the C-terminal domain of the A- and designed B-subunits.

636 **a**,  $A_3(De)_3$  complex structure (De represents the design subunit) in the absence of nucleotides, solved

637 at 2.77 Å resolution. This structure was named as  $A_3(De)_3\_empty$ . **b**,  $A_3(De)_3$  complex structure bound

638 to an AMP-PNP at a catalytic interface (3.44 Å resolution):  $A_3(De)_3\_ANP_{1cat}$ . (C)  $A_3(De)_3$  complex

639 structure bound to 3 ADPs in the catalytic interfaces and 2 ADPs in the designed non-catalytic


640 interfaces (2.9 Å resolution):  $A_3(De)_3\_ (ADP \cdot Pi)_{1cat}(ADP)_{2cat,2non-cat}$ . (D)  $A_3(De)_3$  complex structure

641 bound to 3 ADPs in the catalytic interfaces and an ADP in a designed non-catalytic interface (3.95 Å

642 resolution):  $A_3(De)_3\_ (ADP)_{3cat,1non-cat}$ . (E)  $A_3(De)_3$  complex structure bound to 3 ADPs in the catalytic


643 interfaces and 2 ADPs in the designed non-catalytic interfaces (3.95 Å resolution):

644  $A_3(De)_3\_ (ADP)_{3cat,2non-cat}$ .



646 **Fig. 3. Creation of ATP binding sites in the B-subunit induced conformational changes of the A-**  
647 **subunit and the ring complex.**

648 **a**, The nucleotide binding affinities of the wild-type  $A_3B_3$  and  $A_3(De)_3$  complexes to AMP-PNP (top)  
649 and ADP (bottom), observed by fluorescent polarization experiments. **b**, Superpositions of the three  
650 A-subunit structures in the wild-type  $A_3B_3$  (PDB: 3VR2) (left) and  $A_3(De)_3\_empty$  (PDB: 7COP)  
651 (right), using the  $\beta$ -barrel domains (residues 1-71), together with the close-up views for the structures  
652 around the P-loop. **c**, Ring complex conformations of the wild-type  $A_3B_3$  complex (left) and  
653  $A_3(De)_3\_empty$  (right). The C-terminal domains of A- and B- subunits viewed from the N-terminal  $\beta$ -  
654 barrel side, are shown. The circles and arrows show the central pore and the catalytic interface at which  
655 the largest conformational change is observed. **d**, Superpositions of the three B-subunit structures.




656

657 **Fig. 4. ATP binding to the designed site accelerates rotation rate allosterically.**

658 **a**, A typical rotation time course of the designed  $V_1$  (red) and that of the wild-type  $V_1$  (green)<sup>28</sup>, at 100  
659  $\mu\text{M}$  ATP. The insets show the rotation xy-trajectory. The angle distributions are shown at the bottom.

660 **b**, [ATP] dependence of rotational rates for the wild-type (black)<sup>28</sup>, the designed  $V_1$  (red), the design  
661 mutant K157Q (orange) and the design double mutant K157A/S158A (green). The [ATP], at which  
662 the most accelerated rotation was observed, is highlighted in gray. The rates were plotted with averaged  
663 values using three molecules or more (Supplementary Table 5) and the error bars representing S. D.



665 **Fig. 5. The mechanism of allosteric acceleration, revealed by analysis of rotation sub-steps and**  
666 **solved structures.**

667 **a**, A close-up rotation time course of the design at 100  $\mu\text{M}$  ATP and the rotation xy-trajectory. The  
668 main-pause and sub-pause are black and red, respectively. **b**, Duration times at different [ATP] for the  
669 two pauses for the wild-type  $V_1$  (black), the designed  $V_1$  (red), and the design double mutant  
670 K157A/S158A (green). See Supplementary Fig. 13 for distributions of the duration time. Note that for  
671 the main pauses at 100-3000  $\mu\text{M}$  ATP, two time constants were obtained for each [ATP] assuming  
672 consecutive reactions (see Supplementary Fig. 13). **c**, Structure-based interpretation on the ADP-  
673 release promoted by the allosteric effect. Ellipses indicate A-subunits (cyan) and designed B-subunits  
674 (salmon). Nucleotides are red (or salmon pink) circles. **d**, Comparison of  $A_3(\text{De})_3_{(\text{ADP})_{3\text{cat},1\text{non-cat}}}$   
675 (top) and  $A_3(\text{De})_3_{(\text{ADP})_{3\text{cat},2\text{non-cat}}}$  (bottom). The hexameric structures viewed from the C-terminal  
676 domain of the A- and B-subunit (left) and the structures of the catalytic interfaces and the A-subunits,  
677 which form the closed and open-like conformations, respectively (middle and right). ADP molecules  
678 are shown as red spheres. **e**, A rotation scheme for the wild-type, proposed by Iida *et al.* <sup>28</sup>(left).  
679 Proposed hypothetical rotation scheme for the design (right). ATP and ADP are represented by T and  
680 D, respectively. Red indicates nucleotides bound to non-catalytic interfaces.